• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Transfection Technology Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 Product Image

Transfection Technology Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

  • ID: 2829725
  • April 2014
  • Region: Global
  • 120 Pages
  • Transparency Market Research
The global transfection technology market was valued at USD 386.4 million in 2012 and is expected to grow at a CAGR of 9.7% from 2013 to 2019, to reach an estimated value of USD 768.2 million by 2019.

FEATURED COMPANIES

  • Harvard Bioscience, Inc.
  • Lonza Group Ltd.
  • Merck KGaA
  • Mirus Bio LLC
  • Promega Corporation
  • QIAGEN
  • MORE

'Transfection Technology Market (Reagent-based method, Instrument-based method and Virus-based method) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019'

Transfection is a technique used to introduce nucleic acids (either DNA or RNA) into cells. This technology helps the cells to regulate gene therapy, mutation of cancer cells and protein metabolism by affecting the nuclear genes. The transfection technology market is driven by factors such as increasing demand for protein production, emerging biopharmaceutical market and rising prevalence of cancer and infectious diseases, globally.

The report explains various advancements taking place in this market and analyses the global transfection technology market by types of methods and applications. The method segment of the market is classified as reagent-based method, instrument-based method and virus-based method.

The reagent-based method is further segmented as lipid mediated transfection (Lipofection), calcium phosphate, catonic polymers, DEAE-dextran, activated dendrimers and magnetic beads. Likewise, instrument-based method includes electroporation, biolistic technology, microinjection READ MORE >

The global transfection technology market was valued at USD 386.4 million in 2012 and is expected to grow at a CAGR of 9.7% from 2013 to 2019, to reach an estimated value of USD 768.2 million by 2019.

FEATURED COMPANIES

  • Harvard Bioscience, Inc.
  • Lonza Group Ltd.
  • Merck KGaA
  • Mirus Bio LLC
  • Promega Corporation
  • QIAGEN
  • MORE

Chapter 1 Preface
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
1.4 List of Abbreviations

Chapter 2 Executive Summary
2.1 Market Snapshot: Global Transfection Technology Market (2012 & 2019)
2.1.1 Global Transfection Technology Market, by Methods, 2012 (USD Million)
2.2 Comparative Analysis: Global Transfection Technology Market, By Geography, 2012 and 2019 (Value %)

Chapter 3 Market Overview
3.1 Market Definition and Overview
3.2 Market Dynamics
3.2.1 Drivers
3.2.1.1 Protein production promotes the use of transfection technology methods
3.2.1.2 Emerging biopharmaceutical markets in Asia boost transfection needs
3.2.2. Restraints
3.2.2.1 High cost prevents sufficient market expansion
3.2.3. Opportunities
3.2.3.1 Transfection technologies for stem cell research
3.3 Porters Five Force Analysis for the Global Transfection Technology Market
3.3.1 Bargaining Power of Suppliers
3.3.2 Bargaining Power of Buyers
3.3.3 Threat of Substitutes
3.3.4 Threat of New Entrants
3.3.5 Competitive Rivalry
3.4 Market Attractiveness Analysis
3.5 Competitive Landscape
3.5.1 Market Share Analysis by Key Players, 2012 (Value %)

Chapter 4 Global Transfection Technology Market, by Methods
4.1 Overview
4.1.1 Global Transfection Technology Market Revenue, by Methods, 2011 – 2019 (USD Million)
4.2 Reagent-based Methods
4.2.1 Global Reagent Based Market Revenue, by Types, 2011 – 2019 (USD Million)
4.2.2 Lipid Mediated Transfection (Lipofection)
4.2.2.1 Global Lipid Mediated Transfection Market Revenue, 2011 – 2019 (USD Million)
4.2.3 Calcium Phosphate
4.2.3.1 Global Calcium Phosphate Transfection Market Revenue, 2011 – 2019 (USD Million)
4.2.4 Cationic Polymers
4.2.4.1 Global Cationic Polymer Market Revenue, 2011 – 2019 (USD Million)
4.2.5 DEAE dextran
4.2.5.1 Global DEAE-dextran Market Revenue, 2011 – 2019 (USD Million)
4.2.6 Activated Dendrimers
4.2.6.1 Global Activated Dendrimers Market Revenue, 2011 – 2019 (USD Million)
4.2.7 Magnetic Beads (Magnet-mediated transfection)
4.2.7.1 Global Magnetic Beads Transfection Market Revenue, 2011 – 2019 (USD Million)
4.3 Instrument-based Methods
4.3.1 Global Instrument Based Method Revenue, by Types, 2011 – 2019 (USD Million)
4.3.2 Electroporation
4.3.2.1 Global Electroporation Market Revenue, 2011 – 2019 (USD Million)
4.3.3 Biolistic Technology
4.3.3.1 Global Biolistic Technology Market Revenue, 2011 – 2019 (USD Million)
4.3.4 Microinjection
4.3.4.1 Global Microinjection Market Revenue, 2011 – 2019 (USD Million)
4.3.5 Laserfection
4.3.5.1 Global Biolistic Technology Market Revenue, 2011 – 2019 (USD Million)
4.4 Virus-based Methods
4.4.1 Global Virus Based Method Market Revenue, 2011 – 2019 (USD Million)

Chapter 5 Global Transfection Technology Market, By Application
5.1 Overview
5.1.1 Global Transfection Technology Market Revenue, by Applications, 2011 – 2019 (USD Million)
5.2 Bio-medical Research
5.2.1 Global Bio-medical Research Market Revenue, by Types, 2011 – 2019 (USD Million)
5.2.2 Transgenic Models
5.2.2.1 Global Transgenic Model Market Revenue, 2011 – 2019 (USD Million)
5.2.3. Cancer Research
5.2.3.1 Global Cancer Research Market Revenue, 2011 – 2019 (USD Million)
5.2.4 Gene and Protein Expression Studies
5.2.4.1 Global Gene and Protein Expression Studies Market Revenue, 2011 – 2019 (USD Million)
5.2.5 Cell Based Microarray for Drug Discovery and Development
5.2.5.1 Global Cell Based Microarray for Drug Discovery and Development Market Revenue, 2011 – 2019 (USD Million)
5.3 Therapeutic Delivery
5.3.1 Global Therapeutics Delivery Market Revenue, by Types, 2011 – 2019 (USD Million)
5.3.2 Biotherapeutics
5.3.2.1 Global Biotherapeutics Market Revenue, 2011 – 2019 (USD Million)
5.3.3 Electro-chemotherapy and Electro-immunotherapy
5.3.3.1 Global Electro-chemotherapy and Electro-immunotherapy Market Revenue, 2011 – 2019 (USD Million)
5.4 Protein Production
5.4.1 Global Protein Production Market Revenue, 2011 – 2019 (USD Million)

Chapter 6 Global Transfection Technology Market, by Geography
6.1 Overview
6.1.1 Global Transfection Technology Market Revenue, by Geography, 2011 – 2019 (USD Million)
6.2 North America
6.2.1 North America Transfection Technology Market Revenue, 2011 – 2019 (USD Million)
6.3 Europe
6.3.1 Europe Transfection Technology Market Revenue, 2011 – 2019 (USD Million)
6.4 Asia-Pacific
6.4.1 Asia-Pacific Transfection Technology Market Revenue, 2011 – 2019 (USD Million)
6.5 Rest of the World (RoW)
6.5.1 RoW Transfection Technology Market Revenue, 2011 – 2019 (USD Million)

Chapter 7 Recommendations
7.1 Market Strategy for Success
7.1.1 Develop new technologies and product improvement
7.1.2 Enhance product portfolio for stem cell research transfection
7.2 Barriers and Future Assumptions
7.2.1 High cost is a barrier for sufficient market expansion

Chapter 8 Company Profiles
8.1 Bio-Rad Laboratories, Inc.
8.1.1 Company Overview
8.1.2 Financial Overview
8.1.3 Product Portfolio
8.1.4 Business Strategies
8.1.5 Recent Developments
8.2 Harvard Bioscience, Inc.
8.2.1 Company Overview
8.2.2 Financial Overview
8.2.3 Product Portfolio
8.2.4 Business Strategies
8.2.5 Recent Developments
8.3 Life Technologies Corporation
8.3.1 Company Overview
8.3.2 Financial Overview
8.3.3 Product Portfolio
8.3.4 Business Strategies
8.3.5 Recent Developments
8.4 Lonza Group Ltd.
8.4.1 Company Overview
8.4.2 Financial Overview
8.4.3 Product Portfolio
8.4.4 Business Strategies
8.4.5 Recent Developments
8.5 Merck KGaA
8.5.1 Company Overview
8.5.2 Financial Overview
8.5.3 Product Portfolio
8.5.4 Business Strategies
8.5.5 Recent Developments
8.6 Mirus Bio LLC
8.6.1 Company Overview
8.6.2 Financial Overview
8.6.3 Product Portfolio
8.6.4 Business Strategies
8.6.5 Recent Development
8.7 Polyplus-transfection S.A.
8.7.1 Company Overview
8.7.2 Financial Overview
8.7.3 Product Portfolio
8.7.4 Business Strategies
8.7.5 Recent Developments
8.8 Promega Corporation
8.8.1 Company Overview
8.8.2 Financial Overview
8.8.3 Product Portfolio
8.8.4 Business Strategies
8.8.5 Strategic Alliance
8.8.6 Recent Developments
8.9 QIAGEN
8.9.1 Company Overview
8.9.2 Financial Overview
8.9.3 Product Portfolio
8.9.4 Business Strategies
8.9.5 Recent Developments
8.10 Roche Holding AG
8.10.1 Company Overview
8.10.2 Financial Overview
8.10.3 Product Portfolio
8.10.4 Business Strategies
8.10.5 Recent Development
8.11 Sigma-Aldrich Corporation
8.11.1 Company Overview
8.11.2 Financial Overview
8.11.3 Product Portfolio
8.11.4 Business Strategies
8.11.5 Recent Developments
8.12 SignaGen Laboratories
8.12.1 Company Overview
8.12.2 Financial Overview
8.12.3 Product Portfolio
8.12.4 Recent Developments
8.13 Thermo Fisher Scientific, Inc.
8.13.1 Company Overview
8.13.2 Financial Overview
8.13.3 Product Portfolio
8.13.4 Business Strategies
8.13.5 Recent Developments

List of Figures

FIG. 1 Transfection Technology: Market Segmentation
FIG. 2 Global Transfection Technology Market, by Methods, 2012 (USD Million)
FIG. 3 Comparative Analysis: Global Transfection Technology Market, by Geography, 2012 and 2019 (Value %)
FIG. 4 Porter's Five Forces Analysis: Global Transfection Technology Market
FIG. 5 Market Attractiveness Analysis: Global Transfection Technology Market, by Geography
FIG. 6 Market Share Analysis: Transfection Technology Market, 2012 (Value %)
FIG. 7 Global Lipid Mediated Transfection Market Revenue, 2011 – 2019 (USD Million)
FIG. 8 Global Calcium Phosphate Market Revenue, 2011 – 2019 (USD Million)
FIG. 9 Global Cationic Polymer Market Revenue, 2011 – 2019 (USD Million)
FIG. 10 Global DEAE-dextran Market Revenue, 2011 – 2019 (USD Million)
FIG. 11 Global Activated Dendrimers Market Revenue, 2011 – 2019 (USD Million)
FIG. 12 Global Magnetic Beads Transfection Market Revenue, 2011 – 2019 (USD Million)
FIG. 13 Global Magnetic Beads Market Revenue, 2011 – 2019 (USD Million)
FIG. 14 Global Biolistic Technology Market Revenue, 2011 – 2019 (USD Million)
FIG. 15 Global Microinjection Market Revenue, 2011 – 2019 (USD Million)
FIG. 16 Global Biolistic Technology Market Revenue, 2011 – 2019 (USD Million)
FIG. 17 Global Virus Based Method Market Revenue, 2011 – 2019 (USD Million)
FIG. 18 Global Transgenic Model Market Revenue, 2011 – 2019 (USD Million)
FIG. 19 Global Cancer Research Market Revenue, 2011 – 2019 (USD Million)
FIG. 20 Global Gene and Protein Expression Studies Market Revenue, 2011 – 2019 (USD Million)
FIG. 21 Global Cell Based Microarray for Drug Discovery and Development Market Revenue, 2011 – 2019 (USD Million)
FIG. 22 Global Biotherapeutics Market Revenue, 2011 – 2019 (USD Million)
FIG. 23 Global Electro-chemotherapy and Electro-immunotherapy Market Revenue, 2011 – 2019 (USD Million)
FIG. 24 Global Electro-chemotherapy and Electro-immunotherapy Market Revenue, 2011 – 2019 (USD Million)
FIG. 25 North America Transfection Technology Market Revenue, 2011 – 2019 (USD Million)
FIG. 26 Europe Transfection Technology Market Revenue, 2011 – 2019 (USD Million)
FIG. 27 Asia-Pacific Transfection Technology Market Revenue, 2011 – 2019 (USD Million)
FIG. 28 RoW Transfection Technology Market Revenue, 2011 – 2019 (USD Million)
FIG. 29 Annual Sales: Bio-Rad Laboratories, Inc., Life Science Segment, 2010 – 2012 (USD Million)
FIG. 30 Annual Sales: Harvard Bioscience, Inc., 2010 - 2012 (USD Million)
FIG. 31 Annual Sales: Life Technologies Corporation, 2010 – 2012 (USD Million)
FIG. 32 Annual Sales: Lonza Group Ltd., Bioscience Segment , 2010 – 2012 (USD Million)
FIG. 33 Annual Sales: Merck KGaA, Merck Millipore , 2010 – 2012 (USD Million)
FIG. 34 Annual Sales: QIAGEN, 2010 – 2012 (USD Million)
FIG. 35 Annual Sales: Roche Holding AG, 2010 – 2012 (USD Million)
FIG. 36 Annual Sales: Sigma-Aldrich Corporation, 2010 – 2012 (USD Million)
FIG. 37 Annual Sales: Thermo Fisher Scientific, 2010– 2012 (USD Million)

List of Tables

TABLE 1 List of Abbreviations
TABLE 2 Market Snapshot: Global Transfection Technology Market (2012 & 2019)
TABLE 3 Global Transfection Technology Market Revenue, by Methods, 2011 – 2019 (USD Million)
TABLE 4 Global Reagent Based Market Revenue, by Types, 2011 – 2019 (USD Million)
TABLE 5 Global Instrument Based Market Revenue, by Types, 2011 – 2019 (USD Million)
TABLE 6 Global Transfection Technology Market Revenue, by Applications, 2011 – 2019 (USD Million)
TABLE 7 Global Bio-medical Research Market Revenue, by Types, 2011 – 2019(USD)
TABLE 8 Drug Delivery Methods with their Carriers/Factors
TABLE 9 Global Therapeutics Delivery Market Revenue, by Types, 2011 – 2019 (USD Million)
TABLE 10 Global Transfection Technology Market Revenue, by Geography, 2011 – 2019 (USD Million)

The global transfection technology market was valued at USD 386.4 million in 2012 and is expected to grow at a CAGR of 9.7% from 2013 to 2019, to reach an estimated value of USD 768.2 million by 2019.

FEATURED COMPANIES

  • Harvard Bioscience, Inc.
  • Lonza Group Ltd.
  • Merck KGaA
  • Mirus Bio LLC
  • Promega Corporation
  • QIAGEN
  • MORE

Transfection is a process that involves production of genetically modified cells with the delivery of foreign nucleic acid (DNA or RNA) into the cell. There are two types of transfection technologies that include stable and transient. While stable transfection is permanent and the genes are continually expressed even after the host cell replicates, transient transfected genes are expressed for a limited period of time and are not integrated into the host genome. Increasing prevalence of cancer and growing obese population drives the global transfection technology market. In addition, initiatives taken by various government organizations also further accentuates the growth of this market.

Transfection technologymarket is segmented mainly by types of method and application. The method segment of the market is classified as reagent-based method, instrument-based method and virus-based method. The reagent-based method is further segmented as lipid mediated transfection (Lipofection), calcium phosphate, cationic polymers, DEAE-dextran, activated dendrimers and magnetic beads. Reagent based transfection technology market is experiencing significant growth owing to cost effectiveness and less complicated methods involved during transfection. Likewise, instrument-based method includes electroporation, biolistic technology, microinjection and laserfection.Instrument-based methods are less time consuming and accurate;these advantages drive the growth of this segment.

Transfection technology application market is further segmented as biomedical research, therapeutic delivery and protein production. Rising prevalence of various cancers (prostate, breast and lung), cardiovascular diseases (arrhythmias, ischemic heart disease) and growing mass protein production further accentuates the global transfection technology market. Transfection technologies have also gained widespread popularity because manufacturers are constantly coming up with new and innovative instruments that are easy to use and less complicated.It was also observed that companies who were involved in this market collaborated with the local partners to enter emerging markets of Asia and Africa. For instance, Life Technologies Corporation acquired KDR Biotech Co., Ltd., a South Korea-based distributor of reagents, in April 2013. This acquisition would further enhance Life Technologies Corporation's revenue in the South Korean biotechnology market. Increasing prevalence of infectious diseases (H1N1, H1N5) also accentuates the demand for global transfection technology market. However, cytotoxic effects, technological complications associated with instrument-based and virus-based methods might restrict the demand of the global transfection technology market to a certain level.

North America contributed the largest share, i.e.over 45%, in 2012 of the global transfection technology market. Increasing awareness about transfection applications and various government initiativesare the major factorsdriving the growth of transfection technology market in North America.For instance, in February 2012, National Cancer Institute (NCI) signed a research agreement with Polypus Transfection S.A., a France-based, privately-held company. This agreement includes Polyethylenimine (PEI) reagent from Polypus Transfection S.A that will be utilized by the National Cancer Institute for in-vitro transfection exploration to produce transfected proteins, viruses and antibodies.Europe contributed the second largest share of the total market in 2012.Utilization of nanomedicine in diagnostics, targeted drug delivery, clinical trials and drug development studies is on the peak in Europe. Transfection technologies and reagents are combined with nanoparticles for better efficacy in the above mentioned studies. For instance, the European Commission published in 2011 that it had funded around 200 projects which include utilization of nanomedicine in research and development under sixth and seventh framework program.The Asia-Pacific region is expected to witness the fastest growth (CAGR – more than 10%)due to increasing prevalence of infectious diseases and utilization of biopharmaceuticals for drug discovery and development.

In terms of key players, the global transfection technologymarket is highly fragmented that comprises of Life Technologies Corporation, Lonza Group Ltd, Mirus Bio LLC, Polypus Transfection S.A, Promega Corporation and others.

The global transfection technology market was valued at USD 386.4 million in 2012 and is expected to grow at a CAGR of 9.7% from 2013 to 2019, to reach an estimated value of USD 768.2 million by 2019.

- Bio-Rad Laboratories, Inc.
- Harvard Bioscience, Inc.
- Life Technologies Corporation
- Lonza Group Ltd.
- Merck KGaA
- Mirus Bio LLC
- Polyplus-transfection S.A.
- Promega Corporation
- QIAGEN
- Roche Holding AG
- Sigma-Aldrich Corporation
- SignaGen Laboratories
- Thermo Fisher Scientific, Inc.

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos